- Info
- Significant Ownership
- Insider Ownership
- Insider Trading
- Financials
Significant Ownership of PharmaCyte Biotech, Inc.
- Signature - Title
- /s/ Joshua N. Silverman - Joshua N. Silverman, Chief Executive Officer and President
- Location
- Las Vegas, NV
- Summary
- This page shows a list of all the recent SCHEDULE 13D/G filings made by PharmaCyte Biotech, Inc..
Follow Filing Activity
Follow PharmaCyte Biotech, Inc. and return when a new Schedule 13D/G filing appears.
This tracks SEC filing changes for this page using existing product update flows.
Continue schedule research
Related filing hubs for this reporting manager, useful for reinforcing crawl paths across the schedule cluster.
Significant Ownership of PharmaCyte Biotech, Inc.
| Sym | Company | Class | Ownership | Holdings Value | Net Change | Nb Shares | Change % | Reporting Name | Report Period |
|---|---|---|---|---|---|---|---|---|---|
| QCLS | Q/C TECHNOLOGIES, INC. | Common Stock, par value $0.001 per share | 74% | $28,646,744 | 8,475,368 | PharmaCyte Biotech, Inc. | 14 Nov 2025 | ||
| FEMY | FEMASYS INC | Common Stock, par value $0.0001 per share | 7.9% | $2,762,382 | 4,932,825 | PharmaCyte Biotech, Inc. | 17 Mar 2026 |
Schedules 13D/G Reported by PharmaCyte Biotech, Inc.:
| Sym | Target | Class | Ownership | Change | Current Shares | Change | Value | Reporting name | Form | Report Period | Filing Date |
|---|
* An asterisk sign (*) next to the price indicates that the price is likely invalid.